welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy
study id #: NCT01491555
condition: Duchenne Muscular Dystrophy
Researchers at Children’s Hospital Boston Neurology Department invite children to participate in a new research study. Researchers are looking for boys ages 2 – 30 with Duchenne Muscular Dystrophy (DMD) and healthy boys ages 2 – 30 (without any nerve or muscle concerns) to serve as controls. The study is evaluating a new technique that will test nerve and muscle function. The testing is all pain free. Children participating in the study will come in for 10 visits over two years. Visits will take place every month at first, then less often for the remaining visits. The tests for the study itself take approximately 2hours. If participants are interested or would like to learn more about the study, please call Lavanya Madabusi at 617-919-3554 or Lavanya.Madabusi@childrens.harvard.edu. All inquiries will be kept strictly confidential.
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: April 2012
estimated completion: September 2015
size / enrollment: 73
Characterized by progressive disability leading to death, Duchenne muscular dystrophy (DMD) remains one of the most common and devastating neuromuscular disorders of childhood. Although a variety of promising new treatment strategies are in development, outcome measures for clinical trials remain limited for the most part to a set of functional measures, such as the six-minute walk test. While clearly useful, such measures are impacted by unrelated factors, such as mood and effort, and have limited repeatability. To address this and other limitations, magnetic resonance imaging (MRI) is now being investigated as a surrogate measure. However, more easily applied, cost-effective, office-based surrogate measures that provide high repeatability and sensitivity while still correlating strongly to disease status would find wider use in Phase II and possibly in Phase III clinical trials in DMD. Quantitative ultrasound (QUS) and electrical impedance myography (EIM) are two techniques that could serve in this role. In QUS, muscle pathology (fibrosis and fatty infiltration) in DMD results in an increase in energy reflected back (backscatter) to the ultrasound. The amount of backscatter can be measured directly by analyzing the raw frequency-based acoustic data or indirectly by controlled processing of the gray-scale image. EIM, in contrast, relies upon the application of localized electrical current and measurement of the resulting surface voltages, but is similarly impacted by the fibrotic changes that develop as muscle disease progresses. Here, the investigators propose to evaluate and compare both methodologies simultaneously in a group of DMD patients and normal subjects in order to assess their ability to identify clinically meaningful alterations in muscle health over short intervals of time. As a final exploratory analysis, the investigators will also study the possibility of combining the two modalities. The results of this work will have broad application as they could be applied to a variety of neuromuscular conditions, including other muscular dystrophies. Thus, the hypothesis of this proposal is that both QUS and EIM can serve as convenient, non-invasive, clinically meaningful surrogate markers of disease progression in DMD that surpass the functional measures currently in use.
- The rate of decline of DMD patients versus normal subjects as assessed by EIM and quantitative ultrasound [ Time Frame: up to 45 months ]
With the successful completion of this aim, the investigators will establish that alterations in both EIM and QUS provide meaningful surrogate measures of disease progression in DMD.
- The rate of decline of DMD patients versus normal subjects as assessed by handheld dynamometry, 6-minute walk, and other functional tests. [ Time Frame: up to 45 months ]
With the successful completion of this aim, the investigators will establish that alterations in functional assessments may provide additional meaningful surrogate measures of disease progression in DMD.
Inclusion criteria (DMD):
• Genetically or histologically established diagnosis of DMD
• Male, age 2 – 30
Inclusion criteria (Control):
• Male, age 2 – 30
Exclusion criteria (DMD):
• Presence of implanted pacemaker or other electrical device
• Presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health
Exclusion criteria (control):
• Presence or past history of a neuromuscular disorder or other disease that substantially impacts health
• Presence of implanted pacemaker or other electrical device.
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyThis is a Phase 1, double-blind, placebo...
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory AdolescentsThis single center open-label pilot stud...
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
DMD Gene Therapy Clinical Trial: Making a Difference by Gene Replacement (Dr. Jerry Mendell)https://www.youtube.com/watch?v=AeTqv29h...
Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular DystrophyBackground: - Duchenne muscular dystrop...
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyThe objective is to determine whether ne...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
DMD clinical therapies II: P.135 DMD-HUB: expanding clinical trial capacity for Duchenne muscular dystrophy, 1 year ...The need to increase capacity for Duchen...
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...